PASG · NASDAQ
Average $15.81 (+339.2% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| TD Cowen | Apr 21, 2026 | Downgrade | Buy → Hold |
| Chardan Capital | Apr 21, 2026 | Downgrade | Buy → Neutral |
| Oppenheimer | Apr 21, 2026 | Maintains | Outperform |
| Wedbush | Apr 21, 2026 | Downgrade | Outperform → Neutral |
| Oppenheimer | Mar 31, 2026 | Initiates | Outperform |
| Canaccord Genuity | Mar 4, 2026 | Maintains | Buy |
| Chardan Capital | Nov 12, 2025 | Maintains | Buy |
Updated Aug 25, 2026
Passage Bio is positioned for success with their strong focus on genetic medicines, cutting-edge technology, and a promising pipeline led by their lead candidate PBFT02. They have a strong financial outlook with a conservative approach, reflected in their target price of $23 per share based on a sum-of-the-parts peak revenue analysis and a 12% discount rate.
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases, which poses typical upsides and downsides for a biotech company. Recently, the company faced safety issues and had to amend protocols for its lead programs, and competition in the industry may further delay trials or impact commercial potential. With cash overhang and potentially limited access to future financing, Passage Bio faces significant risks in progressing their pipeline and achieving regulatory approvals.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
